Subjects -> MEDICAL SCIENCES (Total: 8359 journals)
    - ANAESTHESIOLOGY (119 journals)
    - CARDIOVASCULAR DISEASES (329 journals)
    - DENTISTRY (288 journals)
    - ENDOCRINOLOGY (148 journals)
    - FORENSIC SCIENCES (41 journals)
    - HEMATOLOGY (153 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (164 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2268 journals)
    - NURSES AND NURSING (356 journals)
    - OBSTETRICS AND GYNECOLOGY (202 journals)
    - ONCOLOGY (377 journals)
    - OTORHINOLARYNGOLOGY (80 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (270 journals)
    - PSYCHIATRY AND NEUROLOGY (813 journals)
    - RESPIRATORY DISEASES (102 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (78 journals)
    - SURGERY (393 journals)

RESPIRATORY DISEASES (102 journals)                     

Showing 1 - 102 of 102 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 253)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 16)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 4)
BMJ Open Respiratory Research     Open Access   (Followers: 5)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal  
Canadian Respiratory Journal     Open Access   (Followers: 2)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 100)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 2)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 38)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 11)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 2)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 3)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 15)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 17)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 32)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 37)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  


Similar Journals
Journal Cover
The Lancet Respiratory Medicine
Journal Prestige (SJR): 7.746
Citation Impact (citeScore): 5
Number of Followers: 32  
  Full-text available via subscription Subscription journal
ISSN (Print) 2213-2600 - ISSN (Online) 2213-2600
Published by Elsevier Homepage  [3161 journals]
  • [Correspondence] Estimating the hidden burden of obstructive sleep apnoea:
           challenges and pitfalls
    • Authors: Sergio Garbarino; Nicola Magnavita, Antonio Sanna, Nicola Luigi Bragazzi
      Abstract: Adam Benjafield and colleagues1 should be congratulated for their efforts to estimate the global burden of obstructive sleep apnoea. They did a systematic review of population studies in which obstructive sleep apnoea had been objectively assessed, and extrapolated data to the entire country population as well as to the populations of other countries matched by age, sex, body-mass index, ethnicity, and geographical proximity. However, not all the studies included had done stratified random sampling rather than convenience sampling, and some reported a large dropout of participants.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2020-01
      DOI: 10.1016/S2213-2600(19)30416-3
      Issue No: Vol. 8, No. 1 (2020)
  • [Correspondence] Pulmonary embolism mortality trends in the European
           region—too good to be true'
    • Authors: Lara N Roberts; Martin B Whyte, Roopen Arya
      Abstract: We commend Stefano Barco and colleagues1 on their landmark paper quantifying age-standardised pulmonary embolism mortality rates and trends in Europe. However, we caution that the findings might be overly optimistic. In England, deaths from venous thromboembolism within 90 days of a hospital admission were introduced as a quality indicator within the National Health Service (NHS) Outcomes Framework in 2015.2,3 Although the key data published relate to venous thromboembolism deaths associated with hospitalisation, raw data for number of deaths from venous thromboembolism as recorded in the first part of the death certificate are available from 2007 to 2018.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2020-01
      DOI: 10.1016/S2213-2600(19)30448-5
      Issue No: Vol. 8, No. 1 (2020)
  • [Editorial] Time to wake the giant of obstructive sleep apnoea
    • Authors: The Lancet Respiratory Medicine
      First page: 1
      Abstract: Earlier this year, The Lancet Respiratory Medicine reported staggering global estimates for the number of people aged 30–69 years who are affected by obstructive sleep apnoea (OSA). The figure of nearly a billion adults with mild to severe OSA suggests that the condition is both underdiagnosed and under-recognised. The paper also highlighted the paucity of quality evidence available to derive estimates of the prevalence and burden of OSA. To provide such global data is important because the condition, especially severe OSA, is associated with neurocognitive impairment, reduced quality of life, and an increased risk of hypertension, cancer, and metabolic, cardiovascular, and cerebrovascular diseases.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2020-01
      DOI: 10.1016/S2213-2600(19)30449-7
      Issue No: Vol. 8, No. 1 (2020)
  • [Corrections] Correction to Lancet Respir Med 2020; 8: 19
    • Abstract: Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med 2020; 8: 19—In this News piece, the name of the Scientific Director of The Union has been changed to Paula Fujiwara. This correction has been made to the online version as of Nov 15, 2019, and the printed version is correct.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-11-15T23:30:04Z
      DOI: 10.1016/S2213-2600(19)30421-7
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] Pamrevlumab in idiopathic pulmonary fibrosis
    • Authors: Athol U Wells
      Pages: 2 - 3
      Abstract: In The Lancet Respiratory Medicine, Luca Richeldi and colleagues1 report the safety and efficacy of pamrevlumab (FG-3019), a human monoclonal antibody against connective tissue growth factor, in a randomised, double-blind, placebo-controlled phase 2 trial done in patients with idiopathic pulmonary fibrosis. In view of the encouraging observations reported, it should be stressed at the outset that the results must be treated with caution pending an adequately powered phase 3 study. We have been here before: apparently striking treatment effects in idiopathic pulmonary fibrosis have been greeted with enthusiasm, but ultimately led to disappointment, as in an initial report of the efficacy of interferon gamma in idiopathic pulmonary fibrosis, admittedly in a tiny cohort.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-28T22:01:06Z
      DOI: 10.1016/S2213-2600(19)30339-X
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] The long-lasting dark shadow of past and present smoking
    • Authors: Yunus Çolak; Peter Lange
      Pages: 3 - 5
      Abstract: In western Europe and the USA, tobacco consumption peaked during the 1960s and 1970s and declined thereafter, leading to a much lower smoking prevalence nowadays.1,2 Today, despite the high addiction potential of smoking, a substantial proportion of adults in the general population and of patients with chronic obstructive pulmonary disease (COPD) can proudly call themselves former smokers.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-09T22:30:01Z
      DOI: 10.1016/S2213-2600(19)30349-2
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] Next-generation ALK inhibitors: is the median the message'
    • Authors: D Ross Camidge
      Pages: 5 - 7
      Abstract: Oncogenic rearrangements of the ALK gene occur in approximately 4% of non-small-cell lung cancers (NSCLCs). The first-generation ALK inhibitor crizotinib was approved by the US Food and Drug Administration for treatment of advanced ALK-positive NSCLC in 2011. Since then, three next-generation ALK inhibitors—alectinib, ceritinib, and brigatinib—have been approved for use after crizotinib. Lorlatinib has been approved for use after any of these other next-generation inhibitors; alectinib and ceritinib have been approved as first-line treatment instead of crizotinib; and there is also some preliminary positive data for brigatinib in the first-line setting.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-15T22:30:02Z
      DOI: 10.1016/S2213-2600(19)30362-5
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] E-cigarettes and dual nicotine replacement therapy for smoking
    • Authors: Neal L Benowitz
      Pages: 7 - 8
      Abstract: For many years, tobacco control researchers have speculated that nicotine delivery systems that allow the smoker to inhale nicotine similar to a cigarette, but without exposure to tobacco combustion products, would be much more acceptable and attractive to smokers than nicotine medications (nicotine replacement medication; NRT) and would substantially benefit public health.1 Smokers would be able to switch to a satisfying form of nicotine self-administration to manage their nicotine addiction without most of the harm from combusted tobacco.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-09T22:30:05Z
      DOI: 10.1016/S2213-2600(19)30308-X
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] Progress in understanding the molecular pathology and
           microbiology of cystic fibrosis
    • Authors: Burkhard Tümmler
      Pages: 8 - 10
      Abstract: Since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989, cystic fibrosis has become a paradigm for cutting-edge basic, translational, and clinical research, which has transformed a devastating disease of childhood to a chronic condition with a reasonable quality of life that can last for decades. Being a monogenic autosomal recessive trait, cystic fibrosis was one of the first inherited disorders for which the disease-causing lesions were resolved by reverse genetics and subsequent mutation scanning of the affected gene.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-27T22:30:04Z
      DOI: 10.1016/S2213-2600(19)30333-9
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] Clinical care for cystic fibrosis: preparing for the future now
    • Authors: Michael W Konstan; Patrick A Flume
      Pages: 10 - 12
      Abstract: The survival of people with cystic fibrosis has improved dramatically over the past 60 years, such that adult patients now outnumber paediatric patients in some countries.1,2 This improvement can be attributed largely to advances in the treatment of complications of cystic fibrosis, but new therapies that target the underlying cause of cystic fibrosis—the absence or impaired functioning of the cystic fibrosis transmembrane conductance regulator (CFTR) protein—promise to transform health outcomes for patients with the disease.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-27T22:30:04Z
      DOI: 10.1016/S2213-2600(19)30334-0
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] Cystic fibrosis lung disease and bronchiectasis
    • Authors: James D Chalmers
      Pages: 12 - 14
      Abstract: In a Lancet Respiratory Medicine Commission report, experts in cystic fibrosis from 18 countries present their view of the future of cystic fibrosis care.1 The Commission is a landmark at a point in time when the demography and management of cystic fibrosis are changing rapidly. The Commission comprehensively addresses future uncertainties and challenges for the field, including those associated with the management of lung disease.1
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-27T22:30:04Z
      DOI: 10.1016/S2213-2600(19)30335-2
      Issue No: Vol. 8, No. 1 (2019)
  • [Comment] A patient's experience of cystic fibrosis care
    • Authors: Sharon Brennan
      Pages: 14 - 16
      Abstract: Care for people with cystic fibrosis has changed dramatically over my lifetime. The introduction of Pulmyzone (dornase alfa) in the mid-1990s, when I was a teenager, saw my lung function improve so much that I was able to complete a 6-hour moonlight hike through Richmond park, in London, UK, when previously even the short walk to school had left me out of breath. Although that lung capacity was not maintainable, the treatment is no doubt part of the reason why I am still alive at the age of 38 years.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-27T22:30:04Z
      DOI: 10.1016/S2213-2600(19)30336-4
      Issue No: Vol. 8, No. 1 (2019)
  • [News] American Thoracic Society calls for more research into military
           deployment respiratory exposures
    • Authors: Bryant Furlow
      First page: 17
      Abstract: More than 2·7 million US military servicemen and women have served in Afghanistan, Iraq, and surrounding countries since 2001, where they encountered a range of complex respiratory exposures. Among other exposures, more than 80 open-air US military burn pits in Afghanistan and Iraq were used to incinerate hundreds of metric tons of garbage each day. JP-8 jet fuel and diesel that includes naphthalene and other organic compounds were used to keep the fires burning. With housing barracks as close as 30 m from these fires, military personnel and contractors were exposed around the clock to dark plumes of toxic smoke containing benzene, formaldehyde, arsenic, and other chemicals.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-11-15T23:30:04Z
      DOI: 10.1016/S2213-2600(19)30424-2
      Issue No: Vol. 8, No. 1 (2019)
  • [News] US States confront oil and gas drilling health hazards
    • Authors: Bryant Furlow
      First page: 18
      Abstract: In light of findings from a newly released human health risk assessment, Colorado will tighten its regulation of oil and natural gas hydraulic fracturing (fracking) operations near homes, state officials announced Oct 17, 2019.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-11-14T23:30:02Z
      DOI: 10.1016/S2213-2600(19)30423-0
      Issue No: Vol. 8, No. 1 (2019)
  • [News] WHO global progress report on tuberculosis elimination
    • Authors: Emilia Harding
      First page: 19
      Abstract: In the first update on tuberculosis since the UN General Assembly High Level meeting on Sep 26, 2018, in which All UN Member States committed to end the global tuberculosis epidemic by 2030, WHO published the Global Tuberculosis Report on Oct 17, 2019. The report details data from 202 countries and territories that account for more than 99% of the world's population and estimated the number of tuberculosis cases. Ahead of the first 2020 milestone, tuberculosis still accounts for the highest mortality from any infectious diseases worldwide, even surpassing HIV/AIDs, causing 1·5 million deaths in 2018.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-11-06T23:30:03Z
      DOI: 10.1016/S2213-2600(19)30418-7
      Issue No: Vol. 8, No. 1 (2019)
  • [News] US CDC issues guidance on e-cigarette, or vaping, associated lung
    • Authors: Bryant Furlow
      First page: 20
      Abstract: The US Centers for Disease Control and Prevention (CDC) released interim guidance for evaluating and managing patients with e-cigarette, or vaping, associated lung injury (EVALI) on Oct 11, 2019, but offered no definitive answers about what has caused these hospitalisations and deaths nationwide. As of Oct 15, 1479 EVALI cases had been reported in every state except Alaska, and 33 deaths had been confirmed in 24 states.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-25T22:30:03Z
      DOI: 10.1016/S2213-2600(19)30409-6
      Issue No: Vol. 8, No. 1 (2019)
  • [Country in Focus] Surge of respiratory illnesses in children due to fires
           in Brazil's Amazon region
    • Authors: Lise Alves
      Pages: 21 - 22
      Abstract: As thousands of kilometres of forest burned in the Amazon during the months of June through August, the world cried out for the preservation of the largest rainforest in the world. Environmentalists denounced the widespread deforestation of the area, with fires being set in protected areas and even very near indigenous reserves.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-29T23:30:06Z
      DOI: 10.1016/S2213-2600(19)30410-2
      Issue No: Vol. 8, No. 1 (2019)
  • [Spotlight] The General Data Protection Regulation and its effect on
           epidemiological and observational research
    • Authors: Philipp G H Metnitz; Paul Zajic, Andrew Rhodes
      Pages: 23 - 24
      Abstract: May 25, 2018, marks a date that has and will effect clinicians and researchers all over Europe and beyond. On that day, the General Data Protection Regulation (GDPR) legislation became enforced. Since then, it has redefined the way data have to be collected, transmitted, and stored. The protection of personal data is a right guaranteed in the Charter of Fundamental Rights of the EU. The GDPR has been conceived to unify and solidify the implementation of this right all over Europe. Its implications are, therefore, the focus of this article.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-29T23:30:02Z
      DOI: 10.1016/S2213-2600(19)30411-4
      Issue No: Vol. 8, No. 1 (2019)
  • [Articles] Pamrevlumab, an anti-connective tissue growth factor therapy,
           for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised,
           double-blind, placebo-controlled trial
    • Authors: Luca Richeldi; Evans R Fernández Pérez, Ulrich Costabel, Carlo Albera, David J Lederer, Kevin R Flaherty, Neil Ettinger, Rafael Perez, Mary Beth Scholand, Jonathan Goldin, Kin-Hung Peony Yu, Thomas Neff, Seth Porter, Ming Zhong, Eduard Gorina, Elias Kouchakji, Ganesh Raghu
      Pages: 25 - 33
      Abstract: Pamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated. Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-28T22:01:06Z
      DOI: 10.1016/S2213-2600(19)30262-0
      Issue No: Vol. 8, No. 1 (2019)
  • [Articles] Lung function decline in former smokers and low-intensity
           current smokers: a secondary data analysis of the NHLBI Pooled Cohorts
    • Authors: Elizabeth C Oelsner; Pallavi P Balte, Surya P Bhatt, Patricia A Cassano, David Couper, Aaron R Folsom, Neal D Freedman, David R Jacobs, Ravi Kalhan, Amanda R Mathew, Richard A Kronmal, Laura R Loehr, Stephanie J London, Anne B Newman, George T O'Connor, Joseph E Schwartz, Lewis J Smith, Wendy B White, Sachin Yende
      Pages: 34 - 44
      Abstract: Former smokers and low-intensity current smokers have accelerated lung function decline compared with never-smokers. These results suggest that all levels of smoking exposure are likely to be associated with lasting and progressive lung damage.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-09T22:30:04Z
      DOI: 10.1016/S2213-2600(19)30276-0
      Issue No: Vol. 8, No. 1 (2019)
  • [Articles] Efficacy, safety, and biomarker analysis of ensartinib in
           crizotinib-resistant, ALK-positive non-small-cell lung cancer: a
           multicentre, phase 2 trial
    • Authors: Yunpeng Yang; Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Xiaobin Yuan, Yuanqing Fu, Tao Wang, Shanshan Xiao, Li Zhang
      Pages: 45 - 53
      Abstract: Ensartinib has activity and is well tolerated in patients with crizotinib-refractory, ALK-positive NSCLC, including those with brain metastases. The role of ensartinib in patients in whom other second-generation ALK inhibitors have been unsuccessful warrants further studies.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-10-15T22:30:02Z
      DOI: 10.1016/S2213-2600(19)30252-8
      Issue No: Vol. 8, No. 1 (2019)
  • [Articles] Nicotine patches used in combination with e-cigarettes (with
           and without nicotine) for smoking cessation: a pragmatic, randomised trial
    • Authors: Natalie Walker; Varsha Parag, Marjolein Verbiest, George Laking, Murray Laugesen, Christopher Bullen
      Pages: 54 - 64
      Abstract: Combining reduced-harm nicotine products, such as nicotine patches with a nicotine e-cigarette, can lead to a modest improvement in smoking cessation over and above that obtained from using patches plus a nicotine-free e-cigarette (or patches alone), with no indication of any serious harm in the short-term. Future e-cigarette trials should focus on their use alone or in combination with usual smoking cessation support, given issues with differential loss to follow-up and withdrawal if a usual care group is used as a comparator.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-09T22:30:05Z
      DOI: 10.1016/S2213-2600(19)30269-3
      Issue No: Vol. 8, No. 1 (2019)
  • [The Lancet Respiratory Medicine Commission] The future of cystic fibrosis
           care: a global perspective
    • Authors: Scott C Bell; Marcus A Mall, Hector Gutierrez, Milan Macek, Susan Madge, Jane C Davies, Pierre-Régis Burgel, Elizabeth Tullis, Claudio Castaños, Carlo Castellani, Catherine A Byrnes, Fiona Cathcart, Sanjay H Chotirmall, Rebecca Cosgriff, Irmgard Eichler, Isabelle Fajac, Christopher H Goss, Pavel Drevinek, Philip M Farrell, Anna M Gravelle, Trudy Havermans, Nicole Mayer-Hamblett, Nataliya Kashirskaya, Eitan Kerem, Joseph L Mathew, Edward F McKone, Lutz Naehrlich, Samya Z Nasr, Gabriela R Oates, Ciaran O'Neill, Ulrike Pypops, Karen S Raraigh, Steven M Rowe, Kevin W Southern, Sheila Sivam, Anne L Stephenson, Marco Zampoli, Felix Ratjen
      Pages: 65 - 124
      Abstract: The past six decades have seen remarkable improvements in health outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young children. However, although life expectancy for people with cystic fibrosis has increased substantially, the disease continues to limit survival and quality of life, and results in a large burden of care for people with cystic fibrosis and their families. Furthermore, epidemiological studies in the past two decades have shown that cystic fibrosis occurs and is more frequent than was previously thought in populations of non-European descent, and the disease is now recognised in many regions of the world.
      Citation: The Lancet Respiratory Medicine 8, 1 (2020)
      PubDate: 2019-09-27T22:30:04Z
      DOI: 10.1016/S2213-2600(19)30337-6
      Issue No: Vol. 8, No. 1 (2019)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-